Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FOLFOX6 + bevacizumab + Reolysin
- Development stage
- Unknown
- Lead developer
- Oncolytics Biotech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
FOLFOX6 + bevacizumab + Reolysin is a combination therapy regimen that includes a modified FOLFOX6 chemotherapy protocol along with bevacizumab (an angiogenesis inhibitor) and Reolysin (oncolytic virus therapy). ## Components of the Regimen **FOLFOX6 (modified)** consists of: - Oxaliplatin: 85-100 mg/m² administered intravenously over 2 hours - Leucovorin (folinic acid): 400 mg/m² administered intravenously over 2 hours (often concurrent with oxaliplatin) - 5-Fluorouracil (5-FU): Given as both a bolus (400 mg/m²) and a continuous infusion (2,400 mg/m²) over 46 hours[1][4][6] The regimen is typically administered in 2-week cycles, with patients receiving up to 12 cycles depending on their condition and response to treatment[1][5]. While the search results don't specifically mention bevacizumab or Reolysin in combination with FOLFOX6, this combination would likely be used in the treatment of advanced colorectal cancer or potentially other gastrointestinal malignancies.
- Brand names
- EloxatinAvastin
- Other names
- modified FOLFOX6 + bevacizumab + Reolysin
02
Targets
JAM-A (Junctional adhesion molecule A)VEGFA (Vascular endothelial growth factor A)TS (Thymidylate synthase)DNA
Beyond the preview
Go deeper on FOLFOX6 + bevacizumab + Reolysin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FOLFOX6 + bevacizumab + Reolysin.